cyrilzakka/clinical-trials huggingface dataset:
Association of Herpesvirus and Periodontitis

A significant influence of the Herpes viruses family in the progression of periodontal disease has been suggested. The aim of this study was to investigate the potential association of four Herpes viruses (HSV-1, HSV-2, CMV and EBV) with periodontal disease using a qualitative test for evaluating the presence or absence of viral DNA in crevicular fluid samples of both healthy periodontal patients and periodontal compromised patients.

Adult patients with healthy periodontium or periodontally compromised attending the Egas Moniz university dental clinic (Almada, Portugal) are eligible to participate The study involves a periodontal diagnosis and collection of unstimulated crevicular fluid from saliva samples.

There will be no direct benefits for patients, but indirect benefit of advancing science in the study of potential involvment of Herpes viruses in periodontitis. No risks of participating are antecipated as the study material and data will be anonymized.

The study runs from the the Cooperativa de Ensino Egas Moniz and is expected to run for 3 months.


Eligibility Criteria:
Inclusion Criteria:

* Patients (\> 18 years of age) with natural teeth attending clinical appointments at the Egas Moniz university dental clinic;
* Cases (periodontally compromised) included at the Department of Periodontology of the same clinic;
* Controls (periodontally healthy) included at the remaining departments of the same clinic.

Exclusion Criteria:

* Occurrence of a viral infection during the six months prior to the clinical study;
* Exposure to antiviral medication in the six months prior to the survey;
* Clinical history of immunosuppression, either exogenous or endogenous;
* Chemotherapy in the previous six months.
Remicade Infusion Management Program

Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.


Eligibility Criteria:
Inclusion Criteria:

* Subject is a good candidate to receive infliximab as per the Product Monograph
* Subject is prescribed infliximab by an appropriate physician
* Subject receives infusion in a community infusion centre.
* Subject has signed the approved consent form.

Exclusion Criteria:

* Not specified in the protocol
Is Monitoring Activity Important for Short- and Long-term Weight Loss?

This study is comparing the effectiveness of two techniques for monitoring physical activity and energy balance on long-term weight management (two years). The focus is on weight loss, prevention of weight gain, and the maintenance of a healthy weight over time. It is expected that both techniques will benefit long-term weight management.

The major objective of this study is to determine if two techniques for monitoring physical activity and energy balance promote the maintenance of weight loss in healthy overweight and obese individuals. The study compares two approaches designed to help individuals monitor physical activity and to adjust their calorie intake to maintain a reasonable energy balance (bodybugg® \& Step Diet Book systems). Full subject participation in the study spans two years. Participants periodically report to a pre-arranged location to be measured by a qualified fitness professional for height, weight, circumferences, and estimated body fat using a bioelectric impedance scale (body fat scale).

Eligibility Criteria:
Inclusion Criteria:

* Desire to lose weight
* Height: 60-76 inches
* BMI 27-40
* Healthy

Exclusion Criteria:

* Currently enrolled in a weight loss program
* Currently under medical care for obesity treatment
* Using drug, supplement, or similar treatment to promote weight loss
* Have undergone bariatric surgery or have breast implants
* Intend to have surgery within the next 24 months
* Have had an eating disorder
* Are pregnant, breast-feeding, or plan to become pregnant within 24 months
* Are planning an extended vacation, absence, or relocation within 24 months
* Use tobacco products
* Frequently consume 2 or more alcoholic drinks per day
* Use illegal drugs, steroids, or growth hormone
* Use any appetite-affecting medications
* Are eating a physician-supervised diet
* Have other problems that might interfere with ability to participate
GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT

Purpose:The aim of this project is to prospectively determine whether a single dose of GnRH-agonist administered at the time of implantation increases or not the reproductive outcome in patients undergoing in vitro fertilization ( IVF)/ intracytoplasmatic sperm injection(ICSI) triggered by a GnRH-agonist followed by a small bolus of human chorionic gonadotropin (hCG 1500 IU) the day of oocyte retrieval.

It has been reported in previous publications that the ovarian hyperstimulation syndrome (OHSS) was eliminated when GnRH agonist was used to trigger ovulation and the delivery rate has improved after modified luteal support especially when a small bolus of hCG is used on the day of oocyte retrieval. (OMEGA/HCG 1500 IU).

However, a risk difference of 7% in delivery rates is still in favor of HCG trigger. Thus, further modifications in the luteal phase supplementation are required in order to optimise the reproductive outcome after GnRH-agonist triggering.

Recently, many papers showed, that independently of the GnRH analogue used to prevent the premature LH surge, the addition of GnRH-agonist during the luteal phase seems to be beneficial in terms of pregnancy. Nevertheless, their use in practice is not yet admitted because of controversial results in terms of efficacy and safety particularly on the conceptus.

Eligibility Criteria:
Inclusion Criteria:

Female age \< 40 years No uterine (fibroids, mullerian malformations), ovarian ( endometrioma) or adnexa (hydrosalpinx) abnormalities• Baseline FSH and LH \< 12 IU/l.Patients with at least one embryo at transfer time

Exclusion Criteria:

* Very high risk of OHSS (\> 30 follicles \> 12 mm the day of ovulation triggering). • Reduced ovarian reserve

  * Fertilization failure
  * Severe endocrinopathy
  * Azoospermia
Efficacy of Faviprevir in COVID-19 Treatment

Faviprevir in COVID-19 treatment

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Eligibility Criteria:
Inclusion Criteria:

* Patients with covid 19

Exclusion Criteria:

* Allergy or contraindications to faviprevir
Biphasic Calcium Phosphate vs. Hydroxyapatite in Sinus Floor Elevation

Twenty patients scheduled for lateral-window sinus floor Elevation (SFE) are randomized into two groups: use of SYMBIOS® Biphasic Bone Graft Material (Group 1) or of Algipore® Bone Substitution Material (Group 2).

Biopsies are taken 3 months after SFE and during implant surgery after 6 months. One ground section per biopsy (n=40) is stained, scanned, and histomorphometrically analyzed for new bone, old bone, soft tissue, graft, bone infiltration of graft, bone-to-graft contact, and penetration depth.


Eligibility Criteria:
Inclusion Criteria:

1. Capability of giving an informed consent
2. Good health as defined by the subject's medical history
3. Patients age 20-75 years
4. Fully edentulous or partially edentulous patients with unilateral or bilateral missing teeth in the maxillary premolar or molar areas with severe alveolar atrophy and a residual alveolar ridge height of maximal 5 mm requiring a two-staged sinus floor elevation and implant placement.

Exclusion Criteria:

1. Patients without detailed baseline medical data
2. Patients with medical history of local inflammations in the posterior maxilla
3. Skeletal immaturity
4. Patients with osteoporosis in their medical history
5. Patients with severe illnesses, malignant diseases, radiotherapy or chemotherapy in their medical history
6. Patients with pathological fractures
7. Patients treated with bisphosphonates
8. Uncontrolled diabetes mellitus
9. Uncontrolled periodontal diseases
10. Smoking
11. Pregnancy
Validation of the Foot Health Status Questionnaire in French Language

A French foot health survey showed that 73% of people examined felt pain and 38% don't left their home, which suggest a reduction in their life's quality and autonomy. Developed by Paul Bennett, FHSQ is a foot health-specific self administrated questionnaire. It sensitively detects changes in patients' foot health status, whatever their pathology, across multidimensional concepts of their quality of life. Actually, more than 150 scientific publications have cited it. Reliable and valid, it has already been translated and validated in multiple languages, but not in French. The subject of this study is to validate the translated and cross-cultural adapted French version FHSQ-fr through its psychometric results of validity and reliability. The study follows a 2-stage methodology.

The first, already completed, consisted of (back)translating the Australian FHSQ questionnaire into French by a scientific committee in order to obtain a pre-final version.

The second is to validate this final version using appropriate statistical analysis, including correlations studies with other French validated questionnaires, to determine its psychometric characteristics.

To assess validity, 150 volunteers will fill out French validated questionnaires, Foot Function Index (FFI), EuroQuality of life 5D-5L (EQ5D) , Visual Analogic Pain Scale (VAPS), and Short Form 12 Health survey (SF12). They will be evaluated about their pain, morphology, function and posture of their feet as usual at a podiatric school. To assess reliability, 50 respondents from the 150 who didn't receive any treatment after 7 to 10 days, will complete the FHSQ-fr again. It would improve knowledge of the status of foot health and its related quality of life in the general population and those suffering from specific pathologies such as diabetes or rheumatoid arthritis, the effectiveness of certain treatments on the same foot condition, and their evolutions using longitudinal studies in France. At the international, the French future results of studies using this clinimetric tool could be compared with those who come from other countries, and integrated to the Australian author's " Bigdataset" which compares, analyses and predicts more accurately the clinically significant efficacy of a treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Patients coming to IFRES in Alençon (61) France for a pedicure or podiatry appointment,
2. Age \>= 18
3. knowing how to speak, read and write French.

Exclusion Criteria:

1. Have already taking part in this research before the proposition to get in.
Efficacy Basics of Bihemispheric Motorcortex Stimulation After Stroke

The aim of the study is to investigate whether the combination of bihemispheric ("dual") transcranial direct current stimulation (tDCS) and motor training on 5 consecutive days facilitates motor recovery in chronic stroke. Results will be compared to a matched group of patients undergoing anodal tDCS as well as a control group receiving sham tDCS. Functional and structural magnetic resonance imaging (MRI) before/after the intervention and during a 3 month follow-up will help investigating neural correlates of expected changes in motor function of the affected upper extremity.


Eligibility Criteria:
Inclusion Criteria:

* chronic stroke (\>6 months after stroke)
* age: 18 to 80 years
* non-hemorrhagic or hemorrhagic stroke

Exclusion Criteria:

* more than 1 stroke
* severe alcohol disease or drug abuse, severe psychiatric disease like depression or psychosis
* severe cognitive deficits
* severe untreated medical conditions
* other neurologic diseases
* severe microangiopathy
* pregnancy
Effectiveness of Four Mini-screws Supported Hyrax for Maxillary Expansion in Early Adulthood

This study aims to evaluate the Skeletal and Dento-alveolar expansion in adult patents using Four Mini-screws Supported Hyrax in compare with untreated control group.

Aim of the study: To evaluate the Effectiveness of Four Mini-screws Supported Hyrax for Maxillary Expansion in Early Adulthood

Methodology:

* Essential record for orthodontic treatment will be taken.
* impression with bands on upper first molars will be taken.
* Four eyelets will be soldered to the body of the hyrax appliance (size 10, Dentaurum, Germany).
* CBCT will be taken while patient wearing 1 mm thickness vacuum on the lower arch to dis-occlude both arches.
* Delivery, check the retention and fitness of the appliance.
* The appliance will be cemented using band cement(compomer).
* Using 3M contra-angle driver, the screws (Tomas screw size 10, Dentaurum, Germany) will be loaded and inserted.
* Activation of the appliance by opening it two turns immediately, followed by two turns everyday till cross bite correction or appearance of midline diastema.
* Closure of the device, and leave the appliance in-situ for five months as a retention.
* Post-expansion CBCT will be taken and continue fixed orthodontic treatment.

Outcome: skeletal and dento-alveolar expansion will be evaluated

Eligibility Criteria:
Inclusion Criteria:

* Unilateral or bilateral Dental posterior cross-bite
* Skeletal Maxillary constriction
* Male and female patients.
* Chronological age (18-30 years).
* Mid-palatal suture maturation (Grade C,D ) according to F Angileri classification
* Good oral hygiene.
* No craniofacial anomalies or syndromes

Exclusion Criteria:

* Scissor-bite
* Orthodontically-treated
* functional cross bite due to premature occlusal contact
* patients with a syndrome
* cleft patients
* Mid-palatal suture maturation(Grade A.B,E) according to F Angileri classification
Assessment of the Sub-gonal Arterial Revascularization of the Lower Limbs in Critical Ischemia by Venous Allograft Stored at + 4 ° C (ERAV)

The main objective of this study is to assess the 2-year survival with salvage of the lower limb of patients who have undergone subgonal bypass grafting by venous allograft in the treatment of Occlusive Peripheral Arterial Disease (OPAD) in critical ischemia, in the absence of usable great saphenous vein.


Eligibility Criteria:
Inclusion Criteria:

* Man or woman over 18 (under effective contraception, hormonal contraceptive or intrauterine device, if premenopausal).
* Patient with critical ischemia of the lower limb (stage 4-5-6 according to the Rutherford classification) requiring revascularization by sub-gonal bypass
* Patient eligible and scheduled for bypass in venous allograft stored at + 4 ° C with distal anastomosis below the knee
* Patient without usable autologous great Saphenous vein
* Subject affiliated or beneficiary of a social security scheme
* Patient having received the appropriate information concerning the objectives and procedures of the study and having declared his non-objection.

Exclusion Criteria:

* Use of unscheduled allografts
* Patient requiring composite bypass in AGV + autologous venous material or prosthesis
* Patient requiring replacement of infected prostheses
* Patient with acute ischemia
* Patient with severe coagulation disorders
* Patient classified physical status score 4
* Patient participating in another clinical trial
* Potential allergy to the graft
* Protected patients: Adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision
* Pregnant or breastfeeding woman
Glycosaminoglycans During Septic Shock - a Temporal Study

We have previously shown that the plasma level of glycosaminoglycans (GAG) in septic shock patients are elevated compared to controls. The purpose of this study is to investigate the temporal dynamic of the blood level of GAG in ten septic shock patients. In addition, to assess the kinetics of GAG during septic shock we examine the liver function by galactose elimination capacity as well as excreted urinary GAG.


Eligibility Criteria:
Inclusion Criteria:

* 2 out of 4 SIRS criteria, where the circulatory criteria must be fulfilled
* Clinical sepsis is suspected
* Informed consent from relative
* Study subject must be over 18 years old

Exclusion Criteria:

* Pregnancy
* \>24h post sepsis diagnosis
* Ongoing oral or intravenous cortisone treatment for more than one month.
* Malignancy with metastasis
Ductus Venosus Doppler at 16 Weeks in Monochorial Pregnancy

Studies shows that the realization of the Ductus venosus Doppler may improve the screening of the twin-twin transfusion syndrome. In this study, we want to compare the outcome of monochorial pregnancy when this Doppler was performed during the ultrasound at16 weeks, and when it wasn't. In order to do that, we will compile past reports (January 2015/ January 2018) of all monochorial pregnancy handled in the hospital of Montpellier and Kremlin Bicêtre. We will establish if the Doppler was done or not, if the twin-twin transfusion syndrome appears and the neonatal outcome.


Eligibility Criteria:
Inclusion criteria:

* Monochorionic diamniotic twin pregnancies
* Monochorionicity diagnosed at the first-trimester
* Follow up and ultrasound realized at the hospital of Montpellier or Kremlin Bicêtre
* Screening for twin-twin transfusion syndrome achieved

Exclusion criteria:

* Missing ultrasound
* Unregistered outcome of the pregnancy
* Eclampsia and pre-eclampsia
Antiseptic Use and Dressing Application

The purposes of the study are:

1. To compare the local efficacy (skin colonization) of 2 commercialized antiseptics used for the disinfection of the dressing application for an epicutaneocavous catheter (EPI).
2. To evaluate whether the bacteria responsible for nosocomial infection is comparable to the flora diagnosed at the EPI site.

Epicutaneocavous catheter is a significant risk factor for nosocomial infection in newborn infants. These infections have been related to local bacterial colonisation. Therefore thorough disinfection should lower the risk of nosocomial infection. However, the local efficacy of antiseptic use has not yet been clearly evaluated in this situation.

Eligibility Criteria:
Inclusion Criteria:

* All infants admitted to the Neonatal Intensive Care Unit
* Epicutaneocavous catheter insertion indication

Exclusion Criteria:

* Epicutaneocavous catheter not inserted within the Unit
Diffusion-tensor Imaging in Brain Tumors Evaluation

Primary and secondary brain tumors are challenging pathologies regarding diagnosis and treatment. MRI is widely used in the imaging evaluation and surgical planning, due to its spatial resolution and ability of tissular characterization.

In this study patients with suspected brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation. By analyzing collected data from MRI evaluation and patient records regarding surgical and histopathological data our aim is to investigate derived imaging biomarkers with impact in the surgical planning and rehabilitation of the patients.


Eligibility Criteria:
Inclusion Criteria:

* brain tumors confirmed by routine MRI evaluation
* surgical treatment with histopathological diagnosis

Exclusion Criteria:

* MRI contraindications
* past or present neurological or neurosurgical condition, beside the tumor
* pregnancy
Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England

This is a retrospective cohort study to assess the real world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death.

The United Kingdom (UK) is one of the first countries that introduced a mass vaccination campaign for COVID-19 and vaccination of the adult population first focused on the oldest age groups, their carers and health care workers (JCVI, 2020). Three COVID-19 vaccines were licensed and are being used including the Moderna, the BioNTech/Pfizer, and the Oxford/AstraZeneca vaccines. Vaccination with the BioNTech/Pfizer vaccine started in December 2020 and the Oxford/AstraZeneca vaccine started in early January 2021. This study is to primarily assess the effectiveness of the Oxford/AstraZeneca COVID-19 vaccine. Given the known high efficacy of the mRNA vaccines in randomized controlled trials (RCTs) and real-world evidence studies, the study aims also to evaluate the vaccine effectiveness (VE) of other COVID-19 vaccines as a validation of the study's methods. On 16 September 2021 it was announced that Booster doses would be introduced in the UK to address vaccine waning and for groups with a suboptimal response. Little is known about health care resource utilisation (HCRU) and health care costs for those who have had COVID-19 or by individual clinical risk group. The RAVEN study is a retrospective cohort study to assess the real-world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death. Analyses will examine the effectiveness of one and two doses, and booster or other additional doses if applicable. This study's extension (October 2021) adds a more detailed exploration of VE in risk groups and an evaluation of the HCRU by people with COVID-19 compared with those who are vaccinated.

Eligibility Criteria:
Inclusion Criteria:

* Eligible for any COVID-19 vaccination based on age at index date
* Have continuous data coverage for the COVID-19 infection datasets
* Have continuous data coverage in other linked databases for a minimum of 12 months prior to the index date

Exclusion Criteria:

• People with a history of COVID-19 infection (confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or not) prior index date
Central Landmark vs USG for IJV Catheterization

This study is planned to compare right internal jugular vein catheterization entry points determined by ultrasound and the central landmark guided method, and the relationship of each with sternocleidomastoid muscle length and body mass index.


Eligibility Criteria:
Inclusion Criteria:

-patients undergoing cardiovascular surgery who needed to have internal jugular vein catheterization aged 18y or older-

Exclusion Criteria:

-previous neck surgery, burns, limited neck movement, diffuse goiter or bleeding problems
Pregnancy and Fibrinogen Disorders

The aim of this observational study is to evaluate the prevalence of uncomplicated pregnancies in women suffering from congenital fibrinogen disorders (i.e, hypofibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia) as well as to describe pregnancies outcomes in such diseases.

Women with quantitative or qualitative fibrinogen disorders are often more prone to obstetrical complications, from bleeding to recurrent miscarriages or thrombosis. Data on fibrinogen levels variations throughout the pregnancy and on the delivery management are lacking. In this observational study will be include adult women with pas obstetrical history. A general questionnaire on demographics and clinical data will be filled out by the patient's physician. A detailed questionnaire on obstetrical data will also be completed contacting the patient in case of lacking data.

Eligibility Criteria:
Inclusion Criteria:

* Inherited fibrinogen disorders (hypofibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia)
* At lest one past pregnancy
* Adult

Exclusion Criteria:

* No past pregnancy
* Not confirmed fibrinogen disorder